ReviewWorld journal of gastroenterology2013
Mucosal healing and deep remission: what does it mean?
Review in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Journal of Crohn's & colitis · 2020Pooled it
- Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis.Journal of Crohn's & colitis · 2019Trial
- Raising the Bar in Crohn's Disease: Is Transmural Healing Achievable?Diagnostics (Basel, Switzerland) · 2026Review
- Colombian registry of inflammatory bowel disease in pediatrics.Crohn's & colitis 360 · 2026Article
- Patient-derived colon epithelial organoids reveal lipid-related metabolic dysfunction in pediatric ulcerative colitis.Nature communications · 2025Article
- Oxidative Stress-Related Biomarkers in Inflammatory Bowel Disease: Dual Tools for Remission Assessment and Prediction of Treatment Outcome.Antioxidants (Basel, Switzerland) · 2025Article
- Is Deep Remission the Right Time to De-Escalate Biologic Therapy in IBD? A Single-Center Retrospective Study.Biomedicines · 2025Article
- Hydrogen gas and the gut microbiota are potential biomarkers for the development of experimental colitis in mice.Gut microbiome (Cambridge, England) · 2024Article
- Anti-apoptotic genes and non-coding RNAs are potential outcome predictors for ulcerative colitis.Functional & integrative genomics · 2023Article
- Is the microbiome the cause of irritable bowel syndrome and inflammatory bowel disease? Lessons to consider from odontology.International journal of colorectal disease · 2023Review
- Clinical Utility of the Neutrophil-to-Bilirubin Ratio in the Detection of Disease Activity in Ulcerative Colitis.Journal of inflammation research · 2023Article
- Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges.Journal of inflammation research · 2023Review
- Treatment goals in IBD: A perspective from patients and their partners.PEC innovation · 2022Article
- Ectopically Localized Epithelial Cell Clumps in Ulcers Are Derived from Reserved Crypt Stem Cells in a Mouse Model of Ulcerative Colitis.Digestive diseases and sciences · 2022Article
- The Promise of Patient-Derived Colon Organoids to Model Ulcerative Colitis.Inflammatory bowel diseases · 2022Article
- Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives.Diagnostics (Basel, Switzerland) · 2021Review
- Expression profile of the matricellular protein periostin in paediatric inflammatory bowel disease.Scientific reports · 2021Article
- Transcriptional Signatures That Define Ulcerative Colitis in Remission.Inflammatory bowel diseases · 2021Article
- Evaluation of Changes in Gut Microbiota in Patients with Crohn's Disease after Anti-Tnfα Treatment: Prospective Multicenter Observational Study.International journal of environmental research and public health · 2020Observational
- Profound remission in Crohn's disease requiring no further treatment for 3-23 years: a case series.Gut pathogens · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of specific terms under different meanings and varying definitions has always been a source of confusion in science. When we point our efforts towards an evidence based medicine for inflammatory bowel diseases (IBD) the same is true: Terms such as "mucosal healing" or "deep remission" as endpoints in clinical trials or treatment goals in daily patient care may contribute to misconceptions if meanings change over time or definitions are altered. It appears to be useful to first have a look at the development of terms and their definitions, to assess their intrinsic and context-independent problems and then to analyze the different relevance in present-day clinical studies and trials. The purpose of such an attempt would be to gain clearer insights into the true impact of the clinical findings behind the terms. It may also lead to a better defined use of those terms for future studies. The terms "mucosal healing" and "deep remission" have been introduced in recent years as new therapeutic targets in the treatment of IBD patients. Several clinical trials, cohort studies or inception cohorts provided data that the long term disease course is better, when mucosal healing is achieved. However, it is still unclear whether continued or increased therapeutic measures will aid or improve mucosal healing for patients in clinical remission. Clinical trials are under way to answer this question. Attention should be paid to clearly address what levels of IBD activity are looked at. In the present review article authors aim to summarize the current evidence available on mucosal healing and deep remission and try to highlight their value and position in the everyday decision making for gastroenterologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.